37 completed, 18 terminated, 5 active not recruiting, 5 recruiting. 50 Phase 2, 20 Phase 1, 5 Not applicable, 3 Phase 4, 2 Phase 3.
Follow Campath-1H: new trials by email Literature Review of Campath-1H trials Research Report on Campath-1H
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody Daratumumab, Alemtuzumab, Sirolimus - Sickle Cell Disease | Phase 2 | Recruiting | Children's National Research Institute | 12 | 2024-04-03 | 2025-09-26 |
| TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2022-07-13 | 2026-07-30 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
| T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea - Sickle Cell Anemia, Beta-thalassemia Major | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 5 | 2018-08-02 | 2026-08-13 |
| Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis Cyclophosphamide, Mesna, Rituximab - Systemic Sclerosis, Diffuse Sclerosis Systemic | Phase 2 | Recruiting | Paul Szabolcs | 8 | 2018-07-31 | 2026-08-14 |
| Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab - Idiopathic Pulmonary Fibrosis, Emphysema or COPD | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 8 | 2018-04-19 | 2026-01-13 |
| Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Alemtuzumab, Etoposide, Dexamethasone - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 18 | 2015-09-23 | 2024-01-17 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan - SCID, Omenn's Syndrome | Not applicable | Active not recruiting | Masonic Cancer Center, University of Minnesota | 57 | 2012-09-04 | 2026-06-17 |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas alemtuzumab, fludarabine, sirolimus - Ewing Sarcoma, Gastrointestinal Tumor | Phase 1 | Completed | St. Jude Children's Research Hospital | 23 | 2012-08-20 | 2026-02-06 |
| Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders Campath-1H, Clofarabine, Melphalan - Lysosomal Storage Disease, Peroxisomal Disorder | Not applicable | Completed | Masonic Cancer Center, University of Minnesota | 3 | 2012-07-11 | 2017-12-05 |
| Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita alemtuzumab, Fludarabine, Cyclosporins - Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome | Phase 2 | Active not recruiting | Boston Children's Hospital | 40 | 2012-07-01 | 2026-03-27 |
| Autologous Stem Cell Transplantation for Crohn's Disease autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG - Crohn's Disease | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 20 | 2012-06-26 | 2025-12-15 |
| Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis Palifermin, Alemtuzumab - Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 40 | 2012-06-01 | 2019-04-30 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2012-02-01 | 2016-03-17 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
| Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus - Sickle Cell Disease | Phase 1 / Phase 2 | Active not recruiting | University of Illinois at Chicago | 45 | 2011-11-11 | 2026-07-08 |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia alemtuzumab, ofatumumab, biopsy - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Northwestern University | 53 | 2011-06-01 | 2025-05-23 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2010-12-14 | 2023-04-04 |
Showing 20 of 66. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Leukemia (14) · Lymphoma (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Hodgkin Disease (8) · Lymphoma, Non-Hodgkin (7) · Leukemia, Myeloid, Acute (6) · Myelodysplastic Syndromes (6) · Anemia, Aplastic (5) · Multiple Myeloma (5) · Recurrence (5) · Anemia, Sickle Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Mantle-Cell (4) · Myeloproliferative Disorders (4)
M.D. Anderson Cancer Center (15) · Baylor College of Medicine (6) · Masonic Cancer Center, University of Minnesota (5) · Northwestern University (5) · National Cancer Institute (NCI) (4) · Paul Szabolcs (4) · Fred Hutchinson Cancer Center (3) · Dana-Farber Cancer Institute (2) · Mayo Clinic (2) · St. Jude Children's Research Hospital (2) · University of Miami (2) · University of Wisconsin, Madison (2) · Alliance for Clinical Trials in Oncology (1) · Boston Children's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1)
United States (61) · Italy (3) · Sweden (2) · United Kingdom (2) · Iran (1) · Norway (1)
Malcolm K Brenner, MD (3) · Paul Orchard, MD (3) · Paul Szabolcs, MD (3) · Brenda Sandmaier (2) · Issa F. Khouri, MD (2) · Issa F. Khouri, MD, BS (2) · Alasdair Coles, Phd FRCP (1) · Alessandra Ferrajoli, M.D. (1) · Alessandra Ferrajoli, MD (1) · Anas Younes, M.D. (1) · Anna Pawlowska (1) · Anne Angiolillo (1) · Ardeshir Ghavamzadeh, MD (1) · Brando Triplett, MD (1) · Brandon Triplett, MD (1)
PMID 23547837, PMID 24477186, PMID 16123718, PMID 17018123, PMID 18339140, PMID 19863336, PMID 19900571, PMID 21454450, PMID 21566092, PMID 21586746, PMID 21981661, PMID 22067384, PMID 23641902, PMID 25078310, PMID 29226570, PMID 30322319, PMID 31063156, PMID 34086408, PMID 34492682, PMID 35173720, PMID 41536780, PMID 42309868
P30CA015704 (3), U10CA031946 (3), P01CA018029 (2), 2008 (1), P30CA014236 (1), P30CA033572 (1), U01CA097452 (1), U10CA021115 (1), U10CA180821 (1)